ABBOTT PARK, Ill., Oct. 16, 2017
/PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S.
launch of the company's Proclaim™ DRG Neurostimulator System, a new
device designed to deliver stimulation to the dorsal root ganglion
(DRG) and alleviate pain in patients suffering from complex
regional pain syndrome (CRPS) of the lower limbs. With the Proclaim
DRG system, Abbott has added new, patient-centric benefits to a
device capable of delivering the company's sustained and superior
pain relief for patients battling CRPS.
Using Bluetooth® wireless technology, iOS‡ software and a more
intuitive Apple‡ iPod touch‡ mobile digital device as the system's
controller, the Proclaim DRG system is designed to provide patients
new benefits over traditional neurostimulation systems. The
Proclaim DRG platform is magnetic resonance (MR)-conditional and
recharge-free, offering upgradeability and increased battery
capacity over Abbott's previous generation systems.
"Both clinical and real world data have shown that DRG
stimulation produces long-term, meaningful pain relief for patients
with complex regional pain syndromes – like those resulting after
total knee arthroplasty, foot surgery or hernia surgery," said
Timothy Deer, M.D., an
interventional pain physician, president and chief executive
officer of the Spine and Nerve Center of the Virginias in
Charleston, West Virginia, and co-principal investigator of
the ACCURATE study. "The ability to offer DRG stimulation on the
Proclaim platform is a very exciting advancement for those of us
who treat patients with these debilitating conditions and want to
provide relief from hard-to-treat neuropathic conditions."
According to the National Pain Foundation, one in four people in
the world suffers from chronic pain and the condition is a key
driver of visits to physician offices and a reduction in quality of
life. CRPS is a type of chronic pain caused by a malfunction of the
peripheral and central nervous systems due to injury, disease or
trauma. The condition is one of the most difficult types of pain to
treat because of its complexity in intensity and location.
Since Abbott's DRG therapy originally launched in the U.S. in
2016, adoption of the therapy has accelerated quickly and has been
well received by patients in need of targeted stimulation that can
address pain associated with CRPS. To date, implants have been
performed by more than 540 physicians in all 50 states.
Patients who receive the Proclaim DRG system can undergo
magnetic resonance imaging (MRI) in MRI scanners up to 1.5 Tesla
and will not have to recharge their battery over the life of the
device. Abbott has also made the Proclaim DRG system upgradeable
and has increased the battery capacity over Abbott's previous
generation systems.
To provide the most user-friendly experience, the Proclaim DRG
Neurostimulator System also utilizes an iPod touch‡ mobile digital
device as the system's patient controller communicates wirelessly
via Bluetooth® wireless technology. The first generation DRG
system, known as the Axium™ Neurostimulator System, used a larger
controller that did not have Bluetooth® wireless technology.
The Proclaim DRG Neurostimulator System supports Abbott's focus
on helping physicians manage patients with difficult-to-treat
chronic pain in specific areas of the lower body, such as the foot,
knee, hip or groin. Clinical research, such as the ACCURATE study,
has demonstrated that DRG stimulation can provide superior pain
relief in patients with CRPS compared to traditional spinal cord
stimulation therapy. The study also found patients receiving DRG
stimulation reported better therapeutic targeting and a reduction
in paresthesia (the tingling feeling common to traditional SCS)
compared to traditional tonic SCS.
Note: ‡ Indicates a third party trademark, which is
property of its respective owner.
Bluetooth is a registered trademark of Bluetooth SIG,
Inc.
About Abbott's Chronic Pain Portfolio:
Chronic pain affects approximately 1.5 billion people worldwide,
more than heart disease, cancer and diabetes combined. The
condition can negatively impact personal relationships, work
productivity and a patient's daily routine. Abbott is a global
leader in the development of chronic pain therapy solutions and the
only medical device manufacturer in the world to offer
radiofrequency ablation (RFA) and spinal cord stimulation (SCS)
therapy solutions including BurstDR™ stimulation and stimulation of
the dorsal root ganglion (DRG) for the treatment of chronic
pain.
About Abbott:
At Abbott, we're committed to helping
people live their best possible life through the power of health.
For more than 125 years, we've brought new products and
technologies to the world — in nutrition, diagnostics, medical
devices and branded generic pharmaceuticals — that create more
possibilities for more people at all stages of life. Today, 94,000
of us are working to help people live not just longer, but better,
in the more than 150 countries we serve.
Connect with us at www.abbott.com, on Facebook
at www.facebook.com/Abbott and on Twitter @AbbottNews and
@AbbottGlobal.
View original content with
multimedia:http://www.prnewswire.com/news-releases/patients-battling-complex-regional-pain-syndrome-find-a-host-of-new-benefits-in-abbotts-proclaim-drg-system-300536562.html
SOURCE Abbott